QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Cancer Research

Background:

• Polo-like kinase 1 (PLK1) is crucial for cell proliferation and a key target in cancer therapy.
• Tetrahydropteridin derivatives have shown potential as PLK1 inhibitors.

Purpose of the Study:

• To develop a quantitative structure-activity relationship (QSAR) model for tetrahydropteridin derivatives targeting PLK1.
• To identify key molecular descriptors influencing PLK1 inhibitory activity.
• To design novel compounds with potential therapeutic applications against PLK1-related disorders.

Main Methods:

• Development of a QSAR model using a dataset of 68 tetrahydropteridin derivatives, adhering to OECD guidelines.
• Identification of three significant descriptors: maxHaaCH, ATSC7i, and AATS7m.
• Validation of the QSAR model using statistical parameters (r² = 0.8213, r²ext = 0.8771, CCCext = 0.9364).
• Molecular modeling, including docking and dynamics studies of designed compounds (D1-D5) against PDB ID: 2RKU.

Main Results:

• The QSAR model demonstrated high reliability and predictability.
• maxHaaCH showed a positive correlation with pIC50, while ATSC7i and AATS7m exhibited negative correlations.
• Molecular modeling studies identified promising lead compounds for PLK1 inhibition.

Conclusions:

• The developed QSAR model effectively explains structural activity relationships for tetrahydropteridin derivatives.
• The findings provide a foundation for the rational design of potent PLK1 inhibitors.
• This research contributes to the development of novel therapeutic strategies for PLK1-driven cancers.